Partnership Between MAIA Biotechnology and Cromos Pharma

Successful Partnership Between MAIA Biotechnology and Cromos Pharma

MAIA Biotechnology and Cromos Pharma have partnered up in an innovative collaboration to advance cancer treatment. Mutual collaborative efforts are focused on THIO, a groundbreaking telomere-targeting agent for non-small cell lung cancer (NSCLC). In a trial presented at ASCO 2024, THIO demonstrated an impressive 85% disease control rate.

Read more in the press release: https://www.pr.com/press-release/914337

CONTACT

INQUIRY@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.

OUR PUBLICATIONS